Analysis Gufic Biosciences Limited (GUFICBIO)
5/31/2024
Analysis of Gufic Biosciences Limited (GUFICBIO)
Gufic Biosciences Limited has been showing some fluctuations in its stock price recently. The Relative Strength Index (RSI) values have been hovering around the mid-range, indicating a neutral sentiment in the market.The Moving Average Convergence Divergence (MACD) indicator has been showing some negative values, suggesting a possible bearish trend. However, the MACD histogram has been fluctuating around the zero line, indicating indecision in the market.
The stock price has been moving around the Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA) levels, with some deviations observed.
Overall, the stock of Gufic Biosciences Limited seems to be experiencing some uncertainty in the market, with mixed signals from the technical indicators. Traders and investors may need to closely monitor the price movements and wait for clearer signals before making any trading decisions.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions regarding the growth rate of the company for different periods:1. The current year growth rate is estimated to be 7.5%.
2. The next quarter growth rate is projected to be 4.8%.
3. The current quarter growth rate is expected to be 5.6%.
4. The next year growth rate is forecasted to be 9.7%.
5. The average annual growth rate for the next 5 years is estimated to be 11%.
6. The average annual growth rate for the past 5 years was approximately 20.15%.
These estimates suggest that the company is expected to experience moderate growth in the near term, with a slightly higher growth rate projected for the next year. However, the average annual growth rate for the next 5 years is higher, indicating a more optimistic outlook for the company's long-term performance compared to the past 5 years.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions on the future price of the security, with the majority clustering around the median and average values. The current price is below both the median and average forecast, suggesting that there may be potential upside according to analysts' predictions.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The results for the quarter ending on January 31, 2025, were released after hours. The results for the quarter ending on October 31, 2024, were not provided at this time. However, for the quarter ending on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.Financials:
- Cash flow: Operating cash flow TTM is $110,563,000,320 and levered free cash flow TTM is $84,726,874,112.
- Balance sheet: Total cash MRQ is $67,150,000,128, total debt MRQ is $104,590,000,128, current ratio MRQ is 1.037, book value per share MRQ is $4.837, total cash per share MRQ is $4.379, and total debt to equity MRQ is 140.968.
- Profit margin: 26.306%.
- Fiscal year ends: September 30, 2023.
- Income statement: EBITDA is $131,393,000,000, revenue TTM is $381,623,009,280, diluted EPS TTM is $6.43, gross profit TTM is $169,148,000,000, revenue per share TTM is $24.537, net income to common TTM is $100,389,003,264, quarterly revenue growth is -4.3%, and quarterly earnings growth YoY is -2.2%.
- Operating margin: 30.743%.
- Most recent quarter: March 31, 2024.
- Return on assets TTM: 22.073999%.
- Return on equity TTM: 147.25%.
Stock statistics:
- Short ratio: 1.53.
- Float shares: 15,308,320,742.
- Shares short: 99,287,450.
- Average 10-day volume: 46,860,048.
- Average 90-day volume: 57,498,254.
- Shares outstanding: 15,334,099,968.
- Percent held by insiders: 5.22%.
- Percent held by institutions: 57.589%.
- Short percent of shares outstanding: 0.65%.
Valuation metrics:
- PEG ratio: 26.319502.
- Forward PE: 26.319502.
- Trailing PE: 29.59409.
- Enterprise value: $2,950,762,332,160.
- Price to book MRQ: 39.3405.
- Price to sales TTM: 7.646095.
- Enterprise to EBITDA: 22.763.
- Enterprise to revenue: 7.732.
- Market capitalization: $2,917,925,650,432.
Stock price summary:
- Beta: 1.264.
- 50-day moving average: $176.2646.
- 200-day moving average: $181.0429.
- 52-week low: $164.08.
- 52-week high: $199.62.
- 52-week change: 6.853%.
Dividends and splits:
- Payout ratio: 14.93%.
- Dividend date: May 16, 2024.
- Last split date: August 31, 2020.
- Ex-dividend date: May 10, 2024.
- Last split factor: 4-for-1 split.
- Forward annual dividend rate: $1.
- 5-year average dividend yield: 0.73%.
- Forward annual dividend yield: 0.5255%.
- Trailing annual dividend rate: $0.97.
- Trailing annual dividend yield: 0.5097%.
Income statement 💸
Here are the revenue figures for the company over the past four fiscal years:1. Fiscal Year 2023: Sales of $383,285,000,000
2. Fiscal Year 2022: Sales of $394,328,000,000
3. Fiscal Year 2021: Sales of $365,817,000,000
4. Fiscal Year 2020: Sales of $274,515,000,000
From these figures, we can observe the following trends:
- The company experienced a decrease in revenue from FY 2022 to FY 2023.
- Prior to the decrease, there was a consistent growth in revenue from FY 2020 to FY 2022.
- Overall, the company has shown a positive revenue trend over the past four years, with significant growth from FY 2020 to FY 2022.
These revenue figures provide insights into the company's performance and can be used to analyze its financial health and market position.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets include cash, inventory, and receivables, with a significant portion in cash equivalents and short-term investments.
3. Non-current assets consist mainly of investments and advances, along with machinery, furniture, and equipment.
4. Total liabilities have also been increasing, but at a slower pace compared to assets.
5. Shareholders' equity has shown a positive trend, indicating a healthy financial position.
6. The company has been managing its short-term and long-term debts effectively.
7. Accumulated depreciation has been significant, affecting the value of non-current assets.
8. Provision for risks and charges has been relatively stable over the years.
9. The company has been investing in leases, land, and improvements consistently.
10. Overall, the financial health and stability of the company seem to be improving based on the balance sheet data.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. Financing activities show significant fluctuations, with large amounts being spent on common stock repurchase and debt issuance and payments.
4. Investing activities also vary, with significant amounts being spent on the sale and purchase of investments.
5. The end cash position has been fluctuating, but overall, it has shown a positive trend over the years.
6. Interest paid has also varied, but it seems to be relatively stable compared to other financial activities.
7. Income tax paid has fluctuated, but it generally follows the trend of the company's financial performance.
8. The company has been paying dividends consistently over the years, with varying amounts.
9. Stock-based compensation has also been a significant expense for the company.
10. Overall, the company's cash flow statement reflects a mix of operational, financing, and investing activities that impact its financial health and performance.
Earnings estimate
The analysts' estimates for future quarterly and annual earnings per share are as follows:1. Current Quarter (as of June 30, 2024):
- Average Estimate: $1.33
- Low Estimate: $1.27
- High Estimate: $1.36
- Year Ago EPS: $1.26
- Number of Analysts: 26
2. Next Quarter (as of September 30, 2024):
- Average Estimate: $1.53
- Low Estimate: $1.44
- High Estimate: $1.63
- Year Ago EPS: $1.46
- Number of Analysts: 25
3. Current Year (as of September 30, 2024):
- Average Estimate: $6.59
- Low Estimate: $6.43
- High Estimate: $6.92
- Year Ago EPS: $6.13
- Number of Analysts: 39
4. Next Year (as of September 30, 2025):
- Average Estimate: $7.23
- Low Estimate: $6.40
- High Estimate: $7.90
- Year Ago EPS: $6.59
- Number of Analysts: 39
Based on these estimates, we can see a generally positive trend in the expected earnings per share for both the upcoming quarters and the next two years. The average estimates are showing growth compared to the year-ago EPS figures, indicating optimism among analysts regarding the company's performance.
MACD of GUFICBIO
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
